{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,11]],"date-time":"2026-11-11T14:20:28Z","timestamp":1794406828732,"version":"4.9.0"},"reference-count":112,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,11,14]],"date-time":"2022-11-14T00:00:00Z","timestamp":1668384000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"name":"European Alliance of Associations for Rheumatology"}],"content-domain":{"domain":["ard.eular.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Annals of the Rheumatic Diseases"],"published-print":{"date-parts":[[2023,1]]},"DOI":"10.1136\/ard-2022-223357","type":"journal-article","created":{"date-parts":[[2022,11,14]],"date-time":"2022-11-14T13:20:36Z","timestamp":1668432036000},"page":"107-118","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":157,"title":["Safety of synthetic and biological DMARDs: a systematic literature review informing the 2022 update of the EULAR recommendations for the management of rheumatoid arthritis"],"prefix":"10.1016","volume":"82","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1954-0229","authenticated-orcid":false,"given":"Alexandre","family":"Sepriano","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6685-8873","authenticated-orcid":false,"given":"Andreas","family":"Kerschbaumer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7136-5248","authenticated-orcid":false,"given":"Sytske Anne","family":"Bergstra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4302-8877","authenticated-orcid":false,"given":"Josef S","family":"Smolen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5781-158X","authenticated-orcid":false,"given":"D\u00e9sir\u00e9e","family":"van der Heijde","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberto","family":"Caporali","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher J","family":"Edwards","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0340-3580","authenticated-orcid":false,"given":"Patrick","family":"Verschueren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4953-3257","authenticated-orcid":false,"given":"Savia","family":"de Souza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1479-5302","authenticated-orcid":false,"given":"Janet","family":"Pope","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1111-8218","authenticated-orcid":false,"given":"Tsutomu","family":"Takeuchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8242-9262","authenticated-orcid":false,"given":"Kimme","family":"Hyrich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3892-6947","authenticated-orcid":false,"given":"Kevin L","family":"Winthrop","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2108-0030","authenticated-orcid":false,"given":"Daniel","family":"Aletaha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3073-7284","authenticated-orcid":false,"given":"Tanja","family":"Stamm","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1120-4781","authenticated-orcid":false,"given":"Jan W","family":"Schoones","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0577-6620","authenticated-orcid":false,"given":"Robert B M","family":"Landew\u00e9","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1136\/ard-2022-223357_bib1","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1136\/annrheumdis-2019-216655","article-title":"EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2019 update","volume":"79","author":"Smolen","year":"2020","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard-2022-223357_bib2","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1002\/art.41095","article-title":"Cardiovascular safety of tocilizumab versus etanercept in rheumatoid arthritis: a randomized controlled trial","volume":"72","author":"Giles","year":"2020","journal-title":"Arthritis Rheumatol"},{"key":"10.1136\/ard-2022-223357_bib3","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1056\/NEJMoa2109927","article-title":"Cardiovascular and cancer risk with tofacitinib in rheumatoid arthritis","volume":"386","author":"Ytterberg","year":"2022","journal-title":"N Engl J Med"},{"key":"10.1136\/ard-2022-223357_bib4","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1136\/annrheumdis-2013-204317","article-title":"Proposal for a new nomenclature of disease-modifying antirheumatic drugs","volume":"73","author":"Smolen","year":"2014","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard-2022-223357_bib5","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1136\/annrheumdis-2019-216656","article-title":"Efficacy of pharmacological treatment in rheumatoid arthritis: a systematic literature research informing the 2019 update of the EULAR recommendations for management of rheumatoid arthritis","volume":"79","author":"Kerschbaumer","year":"2020","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard-2022-223357_bib6","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1136\/annrheumdis-2019-216653","article-title":"Safety of synthetic and biological DMARDs: a systematic literature review Informing the 2019 update of the EULAR recommendations for the management of rheumatoid arthritis","volume":"79","author":"Sepriano","year":"2020","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard-2022-223357_bib7","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1002\/art.37725","article-title":"Methotrexate saves lives: a pearl of observational research","volume":"65","author":"Landew\u00e9","year":"2013","journal-title":"Arthritis Rheum"},{"key":"10.1136\/ard-2022-223357_bib8","author":"Smolen","year":"2022","journal-title":"EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2022 update"},{"key":"10.1136\/ard-2022-223357_bib9","author":"Kerschbaumer","year":"2022","journal-title":"Efficacy of pharmacological treatment in rheumatoid arthritis: a systematic literature research Informing the 2022 update of the EULAR recommendations for management of rheumatoid arthritis"},{"key":"10.1136\/ard-2022-223357_bib10","author":"Bergstra","year":"2022","journal-title":"Persistence, efficacy and safety of glucocorticoids: a systematic literature review Informing the 2022 update of the EULAR recommendations for the management of rheumatoid arthritis"},{"key":"10.1136\/ard-2022-223357_bib11","series-title":"Evidence-based medicine: how to practice and teach EBM","author":"Sackett","year":"1997"},{"key":"10.1136\/ard-2022-223357_bib12","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1136\/annrheumdis-2021-221575","article-title":"Risk and prognosis of SARS-CoV-2 infection and vaccination against SARS-CoV-2 in rheumatic and musculoskeletal diseases: a systematic literature review to inform EULAR recommendations","volume":"81","author":"Kroon","year":"2022","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard-2022-223357_bib13","doi-asserted-by":"crossref","first-page":"1628","DOI":"10.1136\/annrheumdis-2021-222006","article-title":"EULAR recommendations for the management and vaccination of people with rheumatic and musculoskeletal diseases in the context of SARS-CoV-2: the November 2021 update","volume":"81","author":"Landew\u00e9","year":"2022","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard-2022-223357_bib14","doi-asserted-by":"crossref","first-page":"427","DOI":"10.7326\/0003-4819-144-6-200603210-00010","article-title":"Evaluation of the quality of prognosis studies in systematic reviews","volume":"144","author":"Hayden","year":"2006","journal-title":"Ann Intern Med"},{"key":"10.1136\/ard-2022-223357_bib15","doi-asserted-by":"crossref","first-page":"d5928","DOI":"10.1136\/bmj.d5928","article-title":"The cochrane collaboration's tool for assessing risk of bias in randomised trials","volume":"343","author":"Higgins","year":"2011","journal-title":"BMJ"},{"key":"10.1136\/ard-2022-223357_bib16","doi-asserted-by":"crossref","first-page":"269","DOI":"10.55563\/clinexprheumatol\/ftfgmf","article-title":"Effectiveness and safety of biologic and targeted synthetic disease-modifying anti-rheumatic drugs in elderly patients with rheumatoid arthritis: real-world data from the KOBIO registry","volume":"39","author":"Koh","year":"2021","journal-title":"Clin Exp Rheumatol"},{"key":"10.1136\/ard-2022-223357_bib17","doi-asserted-by":"crossref","first-page":"1595","DOI":"10.1002\/cpt.2415","article-title":"Risk of heart failure in rheumatoid arthritis patients treated with tumor necrosis factor-\u03b1 inhibitors","volume":"110","author":"Chen","year":"2021","journal-title":"Clin Pharmacol Ther"},{"key":"10.1136\/ard-2022-223357_bib18","doi-asserted-by":"crossref","first-page":"1004","DOI":"10.1002\/acr.23737","article-title":"Tocilizumab and the risk of cardiovascular disease: direct comparison among biologic disease-modifying antirheumatic drugs for rheumatoid arthritis patients","volume":"71","author":"Xie","year":"2019","journal-title":"Arthritis Care Res"},{"key":"10.1136\/ard-2022-223357_bib19","doi-asserted-by":"crossref","first-page":"804","DOI":"10.3899\/jrheum.191326","article-title":"Benefits of methotrexate use on cardiovascular disease risk among rheumatoid arthritis patients initiating biologic disease-modifying antirheumatic drugs","volume":"48","author":"Xie","year":"2021","journal-title":"J Rheumatol"},{"key":"10.1136\/ard-2022-223357_bib20","doi-asserted-by":"crossref","first-page":"648","DOI":"10.3899\/jrheum.200265","article-title":"The risk of cardiovascular events associated with disease-modifying antirheumatic drugs in rheumatoid arthritis","volume":"48","author":"Ozen","year":"2021","journal-title":"J Rheumatol"},{"key":"10.1136\/ard-2022-223357_bib21","doi-asserted-by":"crossref","first-page":"e001013","DOI":"10.1136\/rmdopen-2019-001013","article-title":"Incidence of inpatient venous thromboembolism in treated patients with rheumatoid arthritis and the association with switching biologic or targeted synthetic disease-modifying antirheumatic drugs (DMARDs) in the real-world setting","volume":"5","author":"Liang","year":"2019","journal-title":"RMD Open"},{"key":"10.1136\/ard-2022-223357_bib22","doi-asserted-by":"crossref","first-page":"1242","DOI":"10.1016\/j.semarthrit.2021.10.001","article-title":"Risk of venous thromboembolism associated with methotrexate versus hydroxychloroquine for rheumatoid arthritis: a propensity score-matched cohort study","volume":"51","author":"He","year":"2021","journal-title":"Semin Arthritis Rheum"},{"key":"10.1136\/ard-2022-223357_bib23","doi-asserted-by":"crossref","first-page":"17009","DOI":"10.1038\/s41598-021-96508-z","article-title":"Effect of introducing biologics to patients with rheumatoid arthritis on the risk of venous thromboembolism: a nationwide cohort study","volume":"11","author":"Chen","year":"2021","journal-title":"Sci Rep"},{"key":"10.1136\/ard-2022-223357_bib24","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1093\/rheumatology\/keab294","article-title":"Risk of venous thromboembolism associated with tofacitinib in patients with rheumatoid arthritis: a population-based cohort study","volume":"61","author":"Desai","year":"2021","journal-title":"Rheumatology"},{"key":"10.1136\/ard-2022-223357_bib25","doi-asserted-by":"crossref","first-page":"e001201","DOI":"10.1136\/rmdopen-2020-001201","article-title":"Gastrointestinal perforations in patients with rheumatoid arthritis treated with biological disease-modifying antirheumatic drugs in Sweden: a nationwide cohort study","volume":"6","author":"Barbulescu","year":"2020","journal-title":"RMD Open"},{"key":"10.1136\/ard-2022-223357_bib26","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1093\/rheumatology\/keab438","article-title":"Risk of diverticulitis and gastrointestinal perforation in rheumatoid arthritis treated with tocilizumab compared to rituximab or abatacept","volume":"61","author":"Rempenault","year":"2022","journal-title":"Rheumatology"},{"key":"10.1136\/ard-2022-223357_bib27","doi-asserted-by":"crossref","first-page":"320","DOI":"10.3899\/jrheum.210888","article-title":"Characteristics, comorbidities, and outcomes of SARS-CoV-2 infection in patients with autoimmune conditions treated with systemic therapies: a population-based study","volume":"49","author":"Curtis","year":"2022","journal-title":"J Rheumatol"},{"key":"10.1136\/ard-2022-223357_bib28","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.1016\/j.semarthrit.2021.08.010","article-title":"Outcomes of COVID-19 in patients with rheumatoid arthritis: a multicenter research network study in the United States","volume":"51","author":"Raiker","year":"2021","journal-title":"Semin Arthritis Rheum"},{"key":"10.1136\/ard-2022-223357_bib29","doi-asserted-by":"crossref","first-page":"1393","DOI":"10.1136\/annrheumdis-2021-220774","article-title":"Abatacept is second to rituximab at risk of HBsAg reverse seroconversion in patients with rheumatic disease","volume":"80","author":"Chen","year":"2021","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard-2022-223357_bib30","doi-asserted-by":"crossref","first-page":"1249","DOI":"10.1002\/acr.23769","article-title":"Risk for herpes zoster in tofacitinib-treated rheumatoid arthritis patients with and without concomitant methotrexate and glucocorticoids","volume":"71","author":"Curtis","year":"2019","journal-title":"Arthritis Care Res"},{"key":"10.1136\/ard-2022-223357_bib31","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1136\/annrheumdis-2021-220651","article-title":"Risk of herpes zoster (shingles) in patients with rheumatoid arthritis under biologic, targeted synthetic and conventional synthetic DMARD treatment: data from the German rabbit register","volume":"81","author":"Redeker","year":"2022","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard-2022-223357_bib32","doi-asserted-by":"crossref","first-page":"1800","DOI":"10.1002\/art.41754","article-title":"Nonserious infections in patients with rheumatoid arthritis: results from the British Society for rheumatology biologics register for rheumatoid arthritis","volume":"73","author":"Bechman","year":"2021","journal-title":"Arthritis Rheumatol"},{"key":"10.1136\/ard-2022-223357_bib33","doi-asserted-by":"crossref","DOI":"10.1177\/1759720X19878004","article-title":"Indicator opportunistic infections after biological treatment in rheumatoid arthritis, 10 years follow-up in a real-world setting","volume":"11","author":"Leon","year":"2019","journal-title":"Ther Adv Musculoskelet Dis"},{"key":"10.1136\/ard-2022-223357_bib34","doi-asserted-by":"crossref","first-page":"11","DOI":"10.2169\/internalmedicine.8205-21","article-title":"Factors associated with pneumocystis jirovecii pneumonia in patients with rheumatoid arthritis receiving methotrexate: a single-center retrospective study","volume":"61","author":"Ohmura","year":"2022","journal-title":"Intern Med"},{"key":"10.1136\/ard-2022-223357_bib35","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1002\/acr2.11064","article-title":"Risk of serious infection in patients with rheumatoid arthritis treated with biologic versus nonbiologic disease-modifying antirheumatic drugs","volume":"1","author":"Ozen","year":"2019","journal-title":"ACR Open Rheumatol"},{"key":"10.1136\/ard-2022-223357_bib36","doi-asserted-by":"crossref","first-page":"2129","DOI":"10.1007\/s10067-019-04516-2","article-title":"Changing rate of serious infections in biologic-exposed rheumatoid arthritis patients. Data from South American registries biobadabrasil and biobadasar","volume":"38","author":"Ranza","year":"2019","journal-title":"Clin Rheumatol"},{"key":"10.1136\/ard-2022-223357_bib37","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.1016\/j.semarthrit.2019.01.009","article-title":"Abatacept initiation in rheumatoid arthritis and the risk of serious infection: a population-based cohort study","volume":"48","author":"Montastruc","year":"2019","journal-title":"Semin Arthritis Rheum"},{"key":"10.1136\/ard-2022-223357_bib38","doi-asserted-by":"crossref","first-page":"e001389","DOI":"10.1136\/rmdopen-2020-001389","article-title":"Hydroxychloroquine and the risk of respiratory infections among RA patients","volume":"6","author":"Kremer","year":"2020","journal-title":"RMD Open"},{"key":"10.1136\/ard-2022-223357_bib39","doi-asserted-by":"crossref","first-page":"1949","DOI":"10.1093\/rheumatology\/kez530","article-title":"Overall infection risk in rheumatoid arthritis during treatment with abatacept, rituximab and tocilizumab; an observational cohort study","volume":"59","author":"Gr\u00f8n","year":"2020","journal-title":"Rheumatology"},{"key":"10.1136\/ard-2022-223357_bib40","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1002\/acr.23824","article-title":"Risk of hospitalized infection and initiation of abatacept versus tumor necrosis factor inhibitors among patients with rheumatoid arthritis: a propensity score-matched cohort study","volume":"72","author":"Chen","year":"2020","journal-title":"Arthritis Care Res"},{"key":"10.1136\/ard-2022-223357_bib41","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1016\/j.semarthrit.2021.07.004","article-title":"The risk of serious infection in rheumatoid arthritis patients receiving tocilizumab compared with tumor necrosis factor inhibitors in Korea","volume":"51","author":"Jeon","year":"2021","journal-title":"Semin Arthritis Rheum"},{"key":"10.1136\/ard-2022-223357_bib42","article-title":"Association of hospitalised infection with socioeconomic status in patients with rheumatoid arthritis receiving biologics or tofacitinib: a population-based cohort study","volume":"8","author":"Chen","year":"2021","journal-title":"Front Med"},{"key":"10.1136\/ard-2022-223357_bib43","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1080\/13696998.2021.1881525","article-title":"Risk and cost of infection-related hospitalizations in medicare beneficiaries with comorbid rheumatoid arthritis treated with abatacept versus other targeted disease-modifying anti-rheumatic drugs","volume":"24","author":"Patel","year":"2021","journal-title":"J Med Econ"},{"key":"10.1136\/ard-2022-223357_bib44","first-page":"3834","article-title":"Risk of serious infections in arthritis patients treated with biological drugs: a matched cohort study and development of prediction model","volume":"60","author":"Krabbe","year":"2021","journal-title":"Rheumatology"},{"key":"10.1136\/ard-2022-223357_bib45","doi-asserted-by":"crossref","first-page":"e84","DOI":"10.1016\/S2665-9913(19)30137-7","article-title":"Risk of admission to hospital for serious infection after initiating tofacitinib versus biologic Dmards in patients with rheumatoid arthritis: a multidatabase cohort study","volume":"2","author":"Pawar","year":"2020","journal-title":"Lancet Rheumatol"},{"key":"10.1136\/ard-2022-223357_bib46","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1002\/acr.24038","article-title":"Risk of serious infection among initiators of tumor necrosis factor inhibitors plus methotrexate versus triple therapy for rheumatoid arthritis: a cohort study","volume":"72","author":"Kang","year":"2020","journal-title":"Arthritis Care Res"},{"key":"10.1136\/ard-2022-223357_bib47","doi-asserted-by":"crossref","first-page":"e034356","DOI":"10.1136\/bmjopen-2019-034356","article-title":"Tuberculosis among patients treated with TNF inhibitors for rheumatoid arthritis, ankylosing spondylitis and psoriatic arthritis in Slovenia: a cohort study","volume":"10","author":"Rotar","year":"2020","journal-title":"BMJ Open"},{"key":"10.1136\/ard-2022-223357_bib48","doi-asserted-by":"crossref","first-page":"2360","DOI":"10.1093\/rheumatology\/kez604","article-title":"Abatacept in rheumatoid arthritis and the risk of cancer: a world observational post-marketing study","volume":"59","author":"de Germay","year":"2020","journal-title":"Rheumatology"},{"key":"10.1136\/ard-2022-223357_bib49","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1016\/j.semarthrit.2019.03.002","article-title":"Risk of malignancy associated with use of tocilizumab versus other biologics in patients with rheumatoid arthritis: a multi-database cohort study","volume":"49","author":"Kim","year":"2019","journal-title":"Semin Arthritis Rheum"},{"key":"10.1136\/ard-2022-223357_bib50","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s41927-018-0050-7","article-title":"Malignancy risk in Australian rheumatoid arthritis patients treated with anti-tumour necrosis factor therapy: an update from the Australian rheumatology association database (ARAD) prospective cohort study","volume":"3","author":"Staples","year":"2019","journal-title":"BMC Rheumatol"},{"key":"10.1136\/ard-2022-223357_bib51","doi-asserted-by":"crossref","first-page":"669","DOI":"10.3904\/kjim.2016.374","article-title":"Risk of malignancy in patients with rheumatoid arthritis after anti-tumor necrosis factor therapy: results from Korean national health insurance claims data","volume":"34","author":"Jung","year":"2019","journal-title":"Korean J Intern Med"},{"key":"10.1136\/ard-2022-223357_bib52","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1093\/rheumatology\/key352","article-title":"Abatacept initiation in rheumatoid arthritis and the risk of cancer: a population-based comparative cohort study","volume":"58","author":"Montastruc","year":"2019","journal-title":"Rheumatology"},{"key":"10.1136\/ard-2022-223357_bib53","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1093\/rheumatology\/keaa330","article-title":"Lymphoma risks in patients with rheumatoid arthritis treated with biological drugs-a Swedish cohort study of risks by time, drug and lymphoma subtype","volume":"60","author":"Hellgren","year":"2021","journal-title":"Rheumatology"},{"key":"10.1136\/ard-2022-223357_bib54","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1186\/s13075-019-1880-4","article-title":"Drug tolerability and reasons for discontinuation of seven biologics in 4466 treatment courses of rheumatoid arthritis-the answer cohort study","volume":"21","author":"Ebina","year":"2019","journal-title":"Arthritis Res Ther"},{"key":"10.1136\/ard-2022-223357_bib55","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1186\/s13075-020-02232-w","article-title":"Drug retention of 7 biologics and tofacitinib in biologics-na\u00efve and biologics-switched patients with rheumatoid arthritis: the answer cohort study","volume":"22","author":"Ebina","year":"2020","journal-title":"Arthritis Res Ther"},{"key":"10.1136\/ard-2022-223357_bib56","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1186\/s13075-021-02496-w","article-title":"Comparison of the drug retention and reasons for discontinuation of tumor necrosis factor inhibitors and interleukin-6 inhibitors in Japanese patients with elderly-onset rheumatoid arthritis-the answer cohort study","volume":"23","author":"Jinno","year":"2021","journal-title":"Arthritis Res Ther"},{"key":"10.1136\/ard-2022-223357_bib57","doi-asserted-by":"crossref","first-page":"2673","DOI":"10.1007\/s10067-021-05609-7","article-title":"Drug retention of sarilumab, baricitinib, and tofacitinib in patients with rheumatoid arthritis: the answer cohort study","volume":"40","author":"Ebina","year":"2021","journal-title":"Clin Rheumatol"},{"key":"10.1136\/ard-2022-223357_bib58","first-page":"23","article-title":"Casual effect of methotrexate+etanercept\/infliximab on survival of\u00a0patients with\u00a0rheumatoid arthritis","volume":"10","author":"Akhlaghi","year":"2019","journal-title":"Pragmat Obs Res"},{"key":"10.1136\/ard-2022-223357_bib59","doi-asserted-by":"crossref","first-page":"105269","DOI":"10.1016\/j.jbspin.2021.105269","article-title":"All-cause and cause-specific mortality of patients with rheumatoid arthritis in Korea: a nation-wide population-based study","volume":"89","author":"Lee","year":"2022","journal-title":"Joint Bone Spine"},{"key":"10.1136\/ard-2022-223357_bib60","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1136\/annrheumdis-2019-216693","article-title":"Risk of neuroinflammatory events in arthritis patients treated with tumour necrosis factor alpha inhibitors: a collaborative population-based cohort study from Denmark and Sweden","volume":"79","author":"Kopp","year":"2020","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard-2022-223357_bib61","doi-asserted-by":"crossref","DOI":"10.1212\/NXI.0000000000000992","article-title":"Demyelinating events following initiation of Anti-TNF\u03b1 therapy in the British Society for rheumatology biologics registry in rheumatoid arthritis","volume":"8","author":"Taylor","year":"2021","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"10.1136\/ard-2022-223357_bib62","article-title":"Pregnancy outcomes in relation to disease activity and anti-rheumatic treatment strategies in women with rheumatoid arthritis","author":"Hellgren","year":"2021","journal-title":"Rheumatology"},{"key":"10.1136\/ard-2022-223357_bib63","doi-asserted-by":"crossref","first-page":"874","DOI":"10.3899\/jrheum.180486","article-title":"Effect of concomitant disease-modifying antirheumatic drugs and methotrexate administration route on biologic treatment durability in rheumatoid arthritis: OBRI cohort results","volume":"46","author":"Lau","year":"2019","journal-title":"J Rheumatol"},{"key":"10.1136\/ard-2022-223357_bib64","doi-asserted-by":"crossref","first-page":"l67","DOI":"10.1136\/bmj.l67","article-title":"Comparative effectiveness of rituximab, abatacept, and tocilizumab in adults with rheumatoid arthritis and inadequate response to TNF inhibitors: prospective cohort study","volume":"364","author":"Gottenberg","year":"2019","journal-title":"BMJ"},{"key":"10.1136\/ard-2022-223357_bib65","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1016\/j.semarthrit.2020.06.020","article-title":"Discontinuation of biologic therapy due to lack\/loss of response and adverse events is similar between TNFi and non-TNFi class: results from a real-world rheumatoid arthritis cohort","volume":"50","author":"Movahedi","year":"2020","journal-title":"Semin Arthritis Rheum"},{"key":"10.1136\/ard-2022-223357_bib66","doi-asserted-by":"crossref","first-page":"e001174","DOI":"10.1136\/rmdopen-2020-001174","article-title":"Comparative effectiveness of antitumour necrosis factor agents, biologics with an alternative mode of action and tofacitinib in an observational cohort of patients with rheumatoid arthritis in Switzerland","volume":"6","author":"Finckh","year":"2020","journal-title":"RMD Open"},{"key":"10.1136\/ard-2022-223357_bib67","doi-asserted-by":"crossref","first-page":"122","DOI":"10.3899\/jrheum.201248.C1","article-title":"Safety of the methotrexate-leflunomide combination in rheumatoid arthritis: results of a multicentric, registry-based, cohort study (BiobadaBrasil)","volume":"49","author":"Bredemeier","year":"2022","journal-title":"J Rheumatol"},{"key":"10.1136\/ard-2022-223357_bib68","doi-asserted-by":"crossref","first-page":"1589","DOI":"10.1002\/art.41803","article-title":"Cardiovascular safety of hydroxychloroquine in US veterans with rheumatoid arthritis","volume":"73","author":"Faselis","year":"2021","journal-title":"Arthritis Rheumatol"},{"key":"10.1136\/ard-2022-223357_bib69","doi-asserted-by":"crossref","first-page":"798","DOI":"10.1136\/annrheumdis-2021-221915","article-title":"Tofacitinib and risk of cardiovascular outcomes: results from the safety of tofacitinib in routine care patients with rheumatoid arthritis (STAR-RA) study","volume":"81","author":"Khosrow-Khavar","year":"2022","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard-2022-223357_bib70","first-page":"1739","article-title":"Biologic agents reduce cardiovascular events in rheumatoid arthritis not responsive to tumour necrosis factor inhibitors: a national cohort study","volume":"36","author":"Hsieh","year":"2020","journal-title":"Can J Cardiol"},{"key":"10.1136\/ard-2022-223357_bib71","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1002\/acr2.11232","article-title":"Postapproval comparative safety study of tofacitinib and biological disease-modifying antirheumatic drugs: 5-year results from a United States-based rheumatoid arthritis registry","volume":"3","author":"Kremer","year":"2021","journal-title":"ACR Open Rheumatol"},{"key":"10.1136\/ard-2022-223357_bib72","doi-asserted-by":"crossref","first-page":"e001987","DOI":"10.1136\/rmdopen-2021-001987","article-title":"Effects of the COVID-19 pandemic on patients with inflammatory joint diseases in Sweden: from infection severity to impact on care provision","volume":"7","author":"Bower","year":"2021","journal-title":"RMD Open"},{"key":"10.1136\/ard-2022-223357_bib73","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1186\/s13075-019-1921-z","article-title":"Safety of abatacept compared with other biologic and conventional synthetic disease-modifying antirheumatic drugs in patients with rheumatoid arthritis: data from an observational study","volume":"21","author":"Ozen","year":"2019","journal-title":"Arthritis Res Ther"},{"key":"10.1136\/ard-2022-223357_bib74","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1186\/s13075-019-1992-x","article-title":"Comparative risk of malignancies and infections in patients with rheumatoid arthritis initiating abatacept versus other biologics: a multi-database real-world study","volume":"21","author":"Simon","year":"2019","journal-title":"Arthritis Res Ther"},{"key":"10.1136\/ard-2022-223357_bib75","doi-asserted-by":"crossref","first-page":"e001465","DOI":"10.1136\/rmdopen-2020-001465","article-title":"Long-term safety and efficacy of sirukumab for patients with rheumatoid arthritis who previously received sirukumab in randomised controlled trials (SIRROUND-LTE)","volume":"7","author":"Aletaha","year":"2021","journal-title":"RMD Open"},{"key":"10.1136\/ard-2022-223357_bib76","doi-asserted-by":"crossref","first-page":"e001017","DOI":"10.1136\/rmdopen-2019-001017","article-title":"Safety and efficacy of switching from adalimumab to sarilumab in patients with rheumatoid arthritis in the ongoing MONARCH open-label extension","volume":"5","author":"Burmester","year":"2019","journal-title":"RMD Open"},{"key":"10.1136\/ard-2022-223357_bib77","doi-asserted-by":"crossref","first-page":"848","DOI":"10.1136\/annrheumdis-2020-219214","article-title":"Filgotinib versus placebo or adalimumab in patients with rheumatoid arthritis and inadequate response to methotrexate: a phase III randomised clinical trial","volume":"80","author":"Combe","year":"2021","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard-2022-223357_bib78","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1002\/acr2.11188","article-title":"Subcutaneous sarilumab in patients with rheumatoid arthritis who previously received subcutaneous sarilumab or intravenous tocilizumab: an open-label extension of a randomized clinical trial","volume":"2","author":"Emery","year":"2020","journal-title":"ACR Open Rheumatol"},{"key":"10.1136\/ard-2022-223357_bib79","doi-asserted-by":"crossref","first-page":"4991","DOI":"10.1093\/rheumatology\/keab355","article-title":"Long-term safety and efficacy of sarilumab over 5 years in patients with rheumatoid arthritis refractory to TNF inhibitors","volume":"60","author":"Fleischmann","year":"2021","journal-title":"Rheumatology"},{"key":"10.1136\/ard-2022-223357_bib80","doi-asserted-by":"crossref","first-page":"1788","DOI":"10.1002\/art.41032","article-title":"Upadacitinib versus placebo or adalimumab in patients with rheumatoid arthritis and an inadequate response to methotrexate: results of a phase III, double-blind, randomized controlled trial","volume":"71","author":"Fleischmann","year":"2019","journal-title":"Arthritis Rheumatol"},{"key":"10.1136\/ard-2022-223357_bib81","doi-asserted-by":"crossref","first-page":"1112","DOI":"10.1002\/acr.24007","article-title":"Efficacy and safety of long-term baricitinib with and without methotrexate for the treatment of rheumatoid arthritis: experience with baricitinib monotherapy continuation or after switching from methotrexate monotherapy or baricitinib plus methotrexate","volume":"72","author":"Fleischmann","year":"2020","journal-title":"Arthritis Care Res"},{"key":"10.1136\/ard-2022-223357_bib82","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1136\/annrheumdis-2020-218412","article-title":"Switching between Janus kinase inhibitor upadacitinib and adalimumab following insufficient response: efficacy and safety in patients with rheumatoid arthritis","volume":"80","author":"Fleischmann","year":"2021","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard-2022-223357_bib83","doi-asserted-by":"crossref","first-page":"1454","DOI":"10.1136\/annrheumdis-2019-215764","article-title":"Safety and effectiveness of upadacitinib or adalimumab plus methotrexate in patients with rheumatoid arthritis over 48 weeks with switch to alternate therapy in patients with insufficient response","volume":"78","author":"Fleischmann","year":"2019","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard-2022-223357_bib84","doi-asserted-by":"crossref","first-page":"120","DOI":"10.5152\/eurjrheum.2021.19207","article-title":"Long-term safety and efficacy of olokizumab in patients with rheumatoid arthritis and inadequate response to tumor necrosis factor inhibitor therapy in phase II studies","volume":"8","author":"Genovese","year":"2021","journal-title":"Eur J Rheumatol"},{"key":"10.1136\/ard-2022-223357_bib85","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1007\/s40744-019-00167-6","article-title":"Two-year safety and effectiveness of Peficitinib in moderate-to-severe rheumatoid arthritis: a phase IIb, open-label extension study","volume":"6","author":"Genovese","year":"2019","journal-title":"Rheumatol Ther"},{"key":"10.1136\/ard-2022-223357_bib86","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1001\/jama.2019.9055","article-title":"Effect of filgotinib vs placebo on clinical response in patients with moderate to severe rheumatoid arthritis refractory to disease-modifying antirheumatic drug therapy: the finch 2 randomized clinical trial","volume":"322","author":"Genovese","year":"2019","journal-title":"JAMA"},{"key":"10.1136\/ard-2022-223357_bib87","doi-asserted-by":"crossref","first-page":"e000887","DOI":"10.1136\/rmdopen-2018-000887","article-title":"Long-term safety and efficacy of sarilumab plus methotrexate on disease activity, physical function and radiographic progression: 5 years of sarilumab plus methotrexate treatment","volume":"5","author":"Genovese","year":"2019","journal-title":"RMD Open"},{"key":"10.1136\/ard-2022-223357_bib88","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1186\/s13075-020-02387-6","article-title":"Efficacy and safety of upadacitinib over 84 weeks in Japanese patients with rheumatoid arthritis (SELECT-SUNRISE)","volume":"23","author":"Kameda","year":"2021","journal-title":"Arthritis Res Ther"},{"key":"10.1136\/ard-2022-223357_bib89","doi-asserted-by":"crossref","first-page":"3303","DOI":"10.1093\/rheumatology\/keaa084","article-title":"Efficacy and safety of upadacitinib in Japanese patients with rheumatoid arthritis (SELECT-SUNRISE): a placebo-controlled phase IIb\/III study","volume":"59","author":"Kameda","year":"2020","journal-title":"Rheumatology"},{"key":"10.1136\/ard-2022-223357_bib90","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1080\/14397595.2019.1639939","article-title":"Sarilumab monotherapy or in combination with non-methotrexate disease-modifying antirheumatic drugs in active rheumatoid arthritis: a Japan phase 3 trial (HARUKA)","volume":"30","author":"Kameda","year":"2020","journal-title":"Mod Rheumatol"},{"key":"10.1136\/ard-2022-223357_bib91","doi-asserted-by":"crossref","first-page":"1230","DOI":"10.3899\/jrheum.201183","article-title":"Safety and efficacy of filgotinib: up to 4-year results from an open-label extension study of phase II rheumatoid arthritis programs","volume":"48","author":"Kavanaugh","year":"2021","journal-title":"J Rheumatol"},{"key":"10.1136\/ard-2022-223357_bib92","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1136\/annrheumdis-2021-219876","article-title":"Olokizumab, a monoclonal antibody against interleukin 6, in combination with methotrexate in patients with rheumatoid arthritis inadequately controlled by methotrexate: efficacy and safety results of a randomised controlled phase III study","volume":"81","author":"Nasonov","year":"2022","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard-2022-223357_bib93","doi-asserted-by":"crossref","first-page":"1511","DOI":"10.1056\/NEJMoa2008250","article-title":"Trial of upadacitinib or abatacept in rheumatoid arthritis","volume":"383","author":"Rubbert-Roth","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1136\/ard-2022-223357_bib94","doi-asserted-by":"crossref","first-page":"2303","DOI":"10.1016\/S0140-6736(19)30419-2","article-title":"Upadacitinib as monotherapy in patients with active rheumatoid arthritis and inadequate response to methotrexate (select-monotherapy): a randomised, placebo-controlled, double-blind phase 3 study","volume":"393","author":"Smolen","year":"2019","journal-title":"Lancet"},{"key":"10.1136\/ard-2022-223357_bib95","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1136\/annrheumdis-2018-213271","article-title":"Dose reduction of baricitinib in patients with rheumatoid arthritis achieving sustained disease control: results of a prospective study","volume":"78","author":"Takeuchi","year":"2019","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard-2022-223357_bib96","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1136\/annrheumdis-2018-214827","volume":"78","author":"Takeuchi","year":"2019","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard-2022-223357_bib97","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1007\/s40744-021-00280-5","article-title":"Safety and effectiveness of peficitinib (ASP015K) in patients with rheumatoid arthritis: final results (32 months of mean peficitinib treatment) from a long-term, open-label extension study in Japan, Korea, and Taiwan","volume":"8","author":"Takeuchi","year":"2021","journal-title":"Rheumatol Ther"},{"key":"10.1136\/ard-2022-223357_bib98","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1186\/s13075-020-2125-2","article-title":"Safety and effectiveness of peficitinib (ASP015K) in patients with rheumatoid arthritis: interim data (22.7 months mean peficitinib treatment) from a long-term, open-label extension study in Japan, Korea, and Taiwan","volume":"22","author":"Takeuchi","year":"2020","journal-title":"Arthritis Res Ther"},{"key":"10.1136\/ard-2022-223357_bib99","doi-asserted-by":"crossref","first-page":"890","DOI":"10.1136\/annrheumdis-2018-214529","article-title":"Clinical outcomes in patients switched from adalimumab to baricitinib due to non-response and\/or study design: phase III data in patients with rheumatoid arthritis","volume":"78","author":"Tanaka","year":"2019","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard-2022-223357_bib100","doi-asserted-by":"crossref","first-page":"1663","DOI":"10.3899\/jrheum.201376","article-title":"Effects of denosumab in Japanese patients with rheumatoid arthritis treated with conventional antirheumatic drugs: 36-month extension of a phase III study","volume":"48","author":"Tanaka","year":"2021","journal-title":"J Rheumatol"},{"key":"10.1136\/ard-2022-223357_bib101","doi-asserted-by":"crossref","first-page":"1607","DOI":"10.1002\/art.41384","article-title":"Efficacy and safety of upadacitinib monotherapy in methotrexate-naive patients with moderately-to-severely active rheumatoid arthritis (SELECT-EARLY): a multicenter, multi-country, randomized, double-blind, active comparator-controlled trial","volume":"72","author":"van Vollenhoven","year":"2020","journal-title":"Arthritis Rheumatol"},{"key":"10.1136\/ard-2022-223357_bib102","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1136\/annrheumdis-2020-219213","article-title":"Filgotinib in combination with methotrexate or as monotherapy versus methotrexate monotherapy in patients with active rheumatoid arthritis and limited or no prior exposure to methotrexate: the phase 3, randomised controlled finch 3 trial","volume":"80","author":"Westhovens","year":"2021","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard-2022-223357_bib111","doi-asserted-by":"crossref","first-page":"1524","DOI":"10.1136\/annrheumdis-2011-200726","article-title":"Risk of incident cardiovascular events in patients with rheumatoid arthritis: a meta-analysis of observational studies","volume":"71","author":"Avina-Zubieta","year":"2012","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard-2022-223357_bib112","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1136\/annrheumdis-2014-205675","article-title":"Risk of major cardiovascular events in patients with psoriatic arthritis, psoriasis and rheumatoid arthritis: a population-based cohort study","volume":"74","author":"Ogdie","year":"2015","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard-2022-223357_bib113","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1186\/s13075-015-0728-9","article-title":"Incidence of malignancy in adult patients with rheumatoid arthritis: a meta-analysis","volume":"17","author":"Simon","year":"2015","journal-title":"Arthritis Res Ther"},{"key":"10.1136\/ard-2022-223357_bib114","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1002\/acr.20371","article-title":"Systematic review and meta-analysis: anti-tumor necrosis factor \u03b1 therapy and cardiovascular events in rheumatoid arthritis","volume":"63","author":"Barnabe","year":"2011","journal-title":"Arthritis Care Res"},{"key":"10.1136\/ard-2022-223357_bib115","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1136\/annrheumdis-2014-206624","article-title":"The effects of tumour necrosis factor inhibitors, methotrexate, non-steroidal anti-inflammatory drugs and corticosteroids on cardiovascular events in rheumatoid arthritis, psoriasis and psoriatic arthritis: a systematic review and meta-analysis","volume":"74","author":"Roubille","year":"2015","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard-2022-223357_bib116","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1136\/annrheumdis-2016-209389","article-title":"Risk of lymphoma in patients exposed to antitumour necrosis factor therapy: results from the British society for rheumatology biologics register for rheumatoid arthritis","volume":"76","author":"Mercer","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard-2022-223357_bib117","doi-asserted-by":"crossref","first-page":"2675","DOI":"10.1002\/art.38745","article-title":"Herpes zoster and tofacitinib therapy in patients with rheumatoid arthritis","volume":"66","author":"Winthrop","year":"2014","journal-title":"Arthritis Rheumatol"},{"key":"10.1136\/ard-2022-223357_bib118","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1136\/annrheumdis-2021-221276","article-title":"Safety of baricitinib for the treatment of rheumatoid arthritis over a median of 4.6 and up to 9.3 years of treatment: final results from long-term extension study and integrated database","volume":"81","author":"Taylor","year":"2022","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard-2022-223357_bib119","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1136\/annrheumdis-2021-220822","article-title":"Incidence and risk factors for herpes zoster in patients with rheumatoid arthritis receiving upadacitinib: a pooled analysis of six phase III clinical trials","volume":"81","author":"Winthrop","year":"2022","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard-2022-223357_bib120","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1136\/annrheumdis-2021-221051","article-title":"Integrated safety analysis of filgotinib in patients with moderately to severely active rheumatoid arthritis receiving treatment over a median of 1.6 years","volume":"81","author":"Winthrop","year":"2022","journal-title":"Ann Rheum Dis"}],"container-title":["Annals of the Rheumatic Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S000349672408628X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S000349672408628X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/ard-2022-223357","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,20]],"date-time":"2026-05-20T04:02:32Z","timestamp":1779249752000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S000349672408628X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1]]},"references-count":112,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2023,1]]}},"alternative-id":["S000349672408628X"],"URL":"https:\/\/doi.org\/10.1136\/ard-2022-223357","relation":{"has-part":[{"id-type":"doi","id":"https:\/\/doi.org\/10.1136\/ard-2022-223357.supp1","asserted-by":"subject"}]},"ISSN":["0003-4967"],"issn-type":[{"value":"0003-4967","type":"print"}],"subject":[],"published":{"date-parts":[[2023,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Safety of synthetic and biological DMARDs: a systematic literature review informing the 2022 update of the EULAR recommendations for the management of rheumatoid arthritis","name":"articletitle","label":"Article Title"},{"value":"Annals of the Rheumatic Diseases","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1136\/ard-2022-223357","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2023 \u00a9 Author(s) (or their employer(s)) 2023. No commercial re-use. See rights and permissions. Published by Elsevier Inc. Published by Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}